News & Featured Coverage

Supplying Complex, Controversial, And Intercontinental Clinical Trials

ALS: how close are we to a cure?

Interviews: Neurological Breakthroughs and Mindful Living: Janet Qi’s PurMinds Revolution

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

Wonderland 2023: Pureminds NeuroPharma With Janet Qi

PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

Cross Time Report: PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Wonderland Conference Miami: Bridging Psychedelics And Overall Wellness

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Recent Coverage: Psychedelics and health at the forefront for upcoming Wonderland Miami

PurMinds NeuroPharma Chief Innovation Officer to Speak at Wonderland Conference

PurMinds NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply

PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski to the Scientific Advisory Board

PsyCap Recap: PurMinds NeuroPharma

PurMinds: 'A Neuroscience Biopharma Company With A Robust Psychedelic Strategy'

PurMinds Completes Initial Strategic Equity Investment in Israeli Psychedelic Drug Company IMIO Life